105 related articles for article (PubMed ID: 16416673)
1. Metabolism of omeprazole after two oral doses in children 1 to 9 months old.
Hoyo-Vadillo C; Venturelli CR; González H; Romero E; Cervantes R; Mata N; Ortiz AC; Rincón V; Zarate F; Sosa C; Ramírez-Mayans J
Proc West Pharmacol Soc; 2005; 48():108-9. PubMed ID: 16416673
[TBL] [Abstract][Full Text] [Related]
2. Nonlinear kinetics after high-dose omeprazole caused by saturation of genetically variable CYP2C19.
Rost KL; Roots I
Hepatology; 1996 Jun; 23(6):1491-7. PubMed ID: 8675169
[TBL] [Abstract][Full Text] [Related]
3. Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19.
Kim KA; Shon JH; Park JY; Yoon YR; Kim MJ; Yun DH; Kim MK; Cha IJ; Hyun MH; Shin JG
Clin Pharmacol Ther; 2002 Jul; 72(1):90-9. PubMed ID: 12152007
[TBL] [Abstract][Full Text] [Related]
4. CYP2C19- and CYP3A4-dependent omeprazole metabolism in West Mexicans.
Gonzalez HM; Romero EM; Peregrina AA; de J Chávez T; Escobar-Islas E; Lozano F; Hoyo-Vadillo C
J Clin Pharmacol; 2003 Nov; 43(11):1211-5. PubMed ID: 14551175
[TBL] [Abstract][Full Text] [Related]
5. Phenotype-genotype analysis of CYP2C19 in Colombian mestizo individuals.
Isaza C; Henao J; Martínez JH; Sepúlveda Arias JC; Beltrán L
BMC Clin Pharmacol; 2007 Jul; 7():6. PubMed ID: 17623107
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin.
Böttiger Y; Tybring G; Götharson E; Bertilsson L
Clin Pharmacol Ther; 1997 Oct; 62(4):384-91. PubMed ID: 9357389
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of proton pump inhibitors in children.
Litalien C; Théorêt Y; Faure C
Clin Pharmacokinet; 2005; 44(5):441-66. PubMed ID: 15871633
[TBL] [Abstract][Full Text] [Related]
8. Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data.
Schwab M; Klotz U; Hofmann U; Schaeffeler E; Leodolter A; Malfertheiner P; Treiber G
Clin Pharmacol Ther; 2005 Dec; 78(6):627-34. PubMed ID: 16338278
[TBL] [Abstract][Full Text] [Related]
9. Phenocopies of poor metabolizers of omeprazole caused by liver disease and drug treatment.
Rost KL; Brockmöller J; Esdorn F; Roots I
J Hepatol; 1995 Sep; 23(3):268-77. PubMed ID: 8550990
[TBL] [Abstract][Full Text] [Related]
10. Artemisinin induces omeprazole metabolism in human beings.
Svensson US; Ashton M; Trinh NH; Bertilsson L; Dinh XH; Nguyen VH; Nguyen TN; Nguyen DS; Lykkesfeldt J; Le DC
Clin Pharmacol Ther; 1998 Aug; 64(2):160-7. PubMed ID: 9728896
[TBL] [Abstract][Full Text] [Related]
11. Omeprazole disposition in children following single-dose administration.
Kearns GL; Andersson T; James LP; Gaedigk A; Kraynak RA; Abdel-Rahman SM; Ramabadran K; van den Anker JN
J Clin Pharmacol; 2003 Aug; 43(8):840-8. PubMed ID: 12953341
[TBL] [Abstract][Full Text] [Related]
12. High-dose omeprazole: use of a multiple-dose study design to assess bioequivalence and accuracy of CYP2C19 phenotyping.
Kovacs P; Edwards DJ; Lalka D; Scheiwe WM; Stoeckel K
Ther Drug Monit; 1999 Oct; 21(5):526-31. PubMed ID: 10519449
[TBL] [Abstract][Full Text] [Related]
13. Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects.
Tybring G; Böttiger Y; Widén J; Bertilsson L
Clin Pharmacol Ther; 1997 Aug; 62(2):129-37. PubMed ID: 9284848
[TBL] [Abstract][Full Text] [Related]
14. Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19.
Shimatani T; Inoue M; Kuroiwa T; Xu J; Mieno H; Nakamura M; Tazuma S
Clin Pharmacol Ther; 2006 Jan; 79(1):144-52. PubMed ID: 16413249
[TBL] [Abstract][Full Text] [Related]
15. Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4'-hydroxylation phenotype and genotype.
Tanaka M; Ohkubo T; Otani K; Suzuki A; Kaneko S; Sugawara K; Ryokawa Y; Hakusui H; Yamamori S; Ishizaki T
Clin Pharmacol Ther; 1997 Dec; 62(6):619-28. PubMed ID: 9433390
[TBL] [Abstract][Full Text] [Related]
16. The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics.
Ishizawa Y; Yasui-Furukori N; Takahata T; Sasaki M; Tateishi T
Clin Pharmacokinet; 2005; 44(11):1179-89. PubMed ID: 16231968
[TBL] [Abstract][Full Text] [Related]
17. Absolute bioavailability and metabolism of omeprazole in relation to CYP2C19 genotypes following single intravenous and oral administrations.
Uno T; Niioka T; Hayakari M; Yasui-Furukori N; Sugawara K; Tateishi T
Eur J Clin Pharmacol; 2007 Feb; 63(2):143-9. PubMed ID: 17203292
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory effect of troleandomycin on the metabolism of omeprazole is CYP2C19 genotype-dependent.
He N; Huang SL; Zhu RH; Tan ZR; Liu J; Zhu B; Zhou HH
Xenobiotica; 2003 Feb; 33(2):211-21. PubMed ID: 12623762
[TBL] [Abstract][Full Text] [Related]
19. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".
Streetman DS; Bleakley JF; Kim JS; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
Clin Pharmacol Ther; 2000 Oct; 68(4):375-83. PubMed ID: 11061577
[TBL] [Abstract][Full Text] [Related]
20. Determination of CYP2C19 phenotype in black Americans with omeprazole: correlation with genotype.
Marinac JS; Balian JD; Foxworth JW; Willsie SK; Daus JC; Owen R; Flockhart DA
Clin Pharmacol Ther; 1996 Aug; 60(2):138-44. PubMed ID: 8823231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]